Pharma FY01: Domestic vs MNCís - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma FY01: Domestic vs MNCís

May 16, 2001

How did the pharma majors perform against each other in FY01? We present a brief comparison between the top 5 domestic vs multinational pharma companies.

Domestic Pharma Growth in Sales (%) MNC Pharma Growth in Sales (%)
Ranbaxy 4.50% Glaxo Wellcome 5.50%
Cipla 37.90% Hoechst Marion Roussel 1.40%
Sun Pharma 28.70% Pfizer 12.00%
Wockhardt -2.90% Knoll 14.80%
Alembic 9.50% SmithKline Beecham -2.10%
Consolidated growth 13.40% 5.60%
(Note: Top 5 companies have been on the basis of un-audited results declared)

Net sales of Top 5 domestic pharma companies has improved by more than 13% (as against industry average of 9-10%). MNC pharma companies under-performed the domestic peers, as consolidated sales grew by mere 5.6%. This could be attributed to obvious reasons viz. relatively older product portfolio and higher DPCO coverage. While MNCís continued to shy away from launching new products, domestic companies were aggressive in product launches. For example Cipla alone launched more than 100 products during the year across various therapeutic segments. It is estimated that MNCís have contributed only 6-7% of total new product launches during FY01. Domestic companies strategy of identifying and exploring new niche therapeutic segments to offer superior products at competitive prices seems to be paying off.

However, operating margins of Multinational pharma companies inched up further mainly due to relaxation in DPCO during the year. Coming to the operations, most of the MNC pharma companies rationalized their field forces, sold off their real estate and consolidated operations in India. Glaxo, for instance sold off its tail-end brands, as did Hoechst. Indian pharma companies, on the contrary expanded their R&D set ups, filed abbreviated new drug applications (ANDA) to cater to the generic market overseas and bought brands from smaller companies in India.

The multinationals seem quite sure not to launch their blockbuster products in India till the product patent becomes a reality. The trigger for them in the near term seems to be further relaxation of DPCO as they have strong brands in their stable. On the other hand, Indian companies are gearing up to meet the challenge post product patent regime. Who wins the race post 2005, is anybodyís guess right now, but one thing is certain, Indian pharma scene is all set for a battle royal.

Equitymaster requests your view! Post a comment on "Pharma FY01: Domestic vs MNCís". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

A Critical Update on the Market (Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers (Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Apr 9, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS